Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

Inhibition of the vascular endothelial growth factor (VEGF) pathway has failed to improve overall survival of patients with glioblastoma (GBM). We previously showed that angiopoietin-2 (Ang-2) overexpression compromised the benefit from anti-VEGF therapy in a preclinical GBM model. Here we investiga...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Proc Natl Acad Sci U S A
Auteurs principaux: Kloepper, Jonas, Riedemann, Lars, Amoozgar, Zohreh, Seano, Giorgio, Susek, Katharina, Yu, Veronica, Dalvie, Nisha, Amelung, Robin L., Datta, Meenal, Song, Jonathan W., Askoxylakis, Vasileios, Taylor, Jennie W., Lu-Emerson, Christine, Batista, Ana, Kirkpatrick, Nathaniel D., Jung, Keehoon, Snuderl, Matija, Muzikansky, Alona, Stubenrauch, Kay G., Krieter, Oliver, Wakimoto, Hiroaki, Xu, Lei, Munn, Lance L., Duda, Dan G., Fukumura, Dai, Batchelor, Tracy T., Jain, Rakesh K.
Format: Artigo
Langue:Inglês
Publié: National Academy of Sciences 2016
Sujets:
Biological Sciences
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4843473/
https://ncbi.nlm.nih.gov/pubmed/27044098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1525360113
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires